logo-loader
viewSareum Holdings PLC

Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor

Sareum Holdings Plc (LON:SAR) CEO Tim Mitchell updates Proactive London's Andrew Scott on the progress being made by Sierra Oncology – its partner which is taking SRA737 through the clinic.

Sierra is currently using SRA737 in two early-stage ovarian cancer studies: one as a monotherapy and another in combination with low-dose gemcitabine – one of the most commonly-prescribed chemotherapies.

Preliminary data from these trials are expected within the next few months.

Sareum's also been investing a lot of time in its TYK2/JAK1 programme.

It has recently selected two molecules – one targeting autoimmune diseases and the other targeting certain types of leukaemia, lymphoma and solid tumours – for preclinical development.

Quick facts: Sareum Holdings PLC

Price: 0.325 GBX

AIM:SAR
Market: AIM
Market Cap: £9.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Symphony Environmental Technologies has game changing...

Symphony Environmental Technologies PLC (AIM: SYM) CEO Michael Laurier joined Steve Darling from Proactive with news the company has received U.S. Food & Drugs Administration approval or its d2p antimicrobial technology. Laurier discusses what that means for the company and what their...

10 hours, 56 minutes ago

2 min read